Gland Pharma Analyst Rating
based on 12 analysts
41.67%
Buy
0.00%
Hold
58.33%
Sell
Based on 12 analysts offering long term price targets for Gland Pharma. An average target of ₹1811.92
Source: S&P Global Market Intelligence
Gland Pharma Share analysis
Gland Pharma price forecast by 12 analysts
Upside of7.90%
High
₹3120
Target
₹1811.92
Low
₹1138
Gland Pharma target price ₹1811.92, a slight upside of 7.9% compared to current price of ₹1679.2. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Gland Pharma revenue growth forecast
Expected growth rate Q1, FY2027:35.54%
Forecast
Actual
Including amortisation and stock based compensations
Gland Pharma EPS growth forecast
EPS estimate Q1, FY2027:63.45%
Forecast
Actual
Source: S&P Global Market Intelligence
Gland Pharma Performance
Day's Low
Day's High
₹1,670Day's Price Range₹1,704.9552 Week's Low
52 Week's High
₹1,585.752-Week Price Range₹2,220.95
| Returns % | |
| 1 Month Return | -4.8 % |
| 3 Month Return | + 1.76 % |
| 1 Year Return | -13.9 % |
| Market Stats | |
| Previous Close | ₹1,675.85 |
| Open | ₹1,687.05 |
| Volume | 1.17L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹27,609.92Cr |
Gland Pharma Key Statistics
| P/E Ratio | 39.99 |
| PEG Ratio | -90.89 |
| Market Cap | ₹27,609.92 Cr |
| P/B Ratio | 3.37 |
| EPS | 46.9 |
| Dividend Yield | 1.09 |
| Sector | Pharmaceuticals |
| ROE | 12.31 |
Gland Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹27,609.92 Cr | -1.54% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| HOLD | ₹1,57,052.54 Cr | 42.54% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,07,573.44 Cr | 42.63% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹47,201.59 Cr | 6.96% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| BUY | ₹1,16,579.09 Cr | 40.08% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Gland Pharma Mutual Fund Holdings
About Gland Pharma
Gland Pharma's operations include the development, manufacture, and marketing of a wide range of injectable drugs and active pharmaceutical ingredients. The company's product portfolio includes antibiotics, anti-emetics, anti-diabetics, anti-epileptics, and other therapeutic categories. Its top products include cephalosporins, penicillins, and other injectable antibiotics.
Gland Pharma is well known for its popular brands, such as Cephalosporin, Penicillin, and Amikacin. These brands have been widely used in hospitals and clinics across India, as well as in other countries. In addition, the company has developed and launched a wide range of generic and branded injectables, including Cefazolin, Cefuroxime, and Amikacin.
Share Price: ₹1679.20 per share as on 17 Jan, 2025 04:01 PM
Market Capitalisation: ₹27,609.92Cr as of today
Revenue: ₹1,405.83Cr as on September 2024 (Q3 24)
Net Profit: ₹163.53Cr as on September 2024 (Q3 24)
Listing date: 20 Nov, 2020
Chairperson Name: Yiu Kwan Stanley Lau
| Organisation | Gland Pharma |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Gland Pharma Ltd
Gland Pharma Receives Positive USFDA Inspection Report - 18 Jan, 2025
Gland Pharma's Pashamylaram facility successfully passed the US FDA's GMP inspection, receiving an Establishment Inspection Report, indicating adherence to quality standards.Gland Pharma Ltd Sees Third Straight Session Gain - 17 Jan, 2025
Gland Pharma Ltd is up 1.41% today, marking its third consecutive session of gains. However, the stock is down 12.85% over the past year. The Nifty Pharma index has also seen a decline of 1.43% in the last month. Today's trading volume is lower than the monthly average, with a PE ratio of 25.06 based on TTM earnings.Gland Pharma Secures US FDA Approval for Facility - 16 Jan, 2025
Gland Pharma's Dundigal facility in Hyderabad received an Establishment Inspection Report from the US FDA, confirming compliance with Good Manufacturing Practices after a successful inspection.Gland Pharma Downgraded Amid Ongoing Stock Decline - 10 Jan, 2025
Gland Pharma Ltd faced a downgrade from Jefferies to Underweight with a reduced target price. The stock has declined for five consecutive sessions, currently at Rs 1785.Gland Pharma to Trade in Futures and Options - 07 Jan, 2025
The National Stock Exchange will introduce futures and options contracts for Gland Pharma Ltd, starting January 31, 2025, enhancing trading opportunities for investors.Gland Pharma Shows Positive Momentum After Breakout - 06 Jan, 2025
Gland Pharma's stock has reclaimed its 200-day exponential moving average after hitting a 52-week low. Following a consolidation phase, it has broken out with rising volumes, suggesting potential upside. Investors are advised to accumulate shares in the Rs 1,880-1,900 range, targeting Rs 2,175-2,200.Gland Pharma Ltd Rises for Third Consecutive Session - 03 Jan, 2025
Gland Pharma Ltd shares increased by 3.15%, marking the third consecutive day of gains. The stock is currently priced at Rs 1900.05, despite a 3.81% decline over the past year. The stock has gained 5.51% in the last month, outperforming the Nifty Pharma index's 3.86% increase.Gland Pharma Receives 'Hold' Upgrade Amid Challenges - 31 Dec, 2024
Gland Pharma has been upgraded to a 'Hold' rating due to low debt and high institutional holdings. However, it faces long-term growth challenges with declining profits and low ROCE. The stock has returned -1.22% since the upgrade and has underperformed against the BSE 500 index.Gland Pharma Faces Regulatory Observations from France - 26 Dec, 2024
Gland Pharma's subsidiary, Cenexis, received 10 observations from the French drug regulator ANSM following a recent inspection. The company reported a decline in net profit despite a slight revenue increase.Cenexi Receives Observations from ANSM Inspection - 25 Dec, 2024
Gland Pharma's subsidiary Cenexi received 10 observations from the French ANSM after a GMP inspection. The company is committed to addressing these observations.
Insights on Gland Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 30.53% to 32.83% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 1.45K Cr → 1.46K Cr (in ₹), with an average increase of 0.8% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 143.76 Cr → 163.53 Cr (in ₹), with an average increase of 12.1% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 46.6% return, outperforming this stock by 59.8%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 103.2% return, outperforming this stock by 157.7%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.83% of holdings in Sep 2024 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 6.88% to 4.47% in Sep 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.45% to 8.32% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 years, GLAND stock has moved down by -54.5%
Gland Pharma Financials
Index Inclusions
Gland Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.83% | 0.00 | |
| Foreign Institutions | 4.47% | ||
| Mutual Funds | 32.83% | 7.53 | |
| Retail Investors | 8.32% | ||
| Others | 2.54% | 10.52 |
Gland Pharma Key Indicators
Gland Pharma Valuation
Gland Pharma in the last 5 years
Lowest (18.84x)
May 22, 2023
Today (39.99x)
January 17, 2025
Industry (54.95x)
January 17, 2025
Highest (67.14x)
August 12, 2021
Gland Pharma Earnings and Dividends
Gland Pharma Ltd Earnings Results
Gland Pharma Ltd’s net profit fell -15.74% since last year same period to ₹163.53Cr in the Q2 2024-2025. On a quarterly growth basis, Gland Pharma Ltd has generated 13.75% jump in its net profits since last 3-months.
Read More about Earnings ResultsGland Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Gland Pharma Ltd has declared dividend of ₹20 - translating a dividend yield of 1.19%.
Read More about Dividends
Gland Pharma Technicals Summary
Bearish
Neutral
Bullish
Gland Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Gland Pharma Ltd
Gland Pharma Ltd share price today stands at ₹1679.2, Open. ₹1687.05 ; Previous Close. ₹1675.85 ; High. ₹1704.95 ; Low. ₹1670 ; 52 Week High. ₹2220.95 ; 52 Week Low: ₹1585.7.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Gland Pharma Ltd shares.
Gland Pharma Ltd is listed on NSE
Gland Pharma Ltd is listed on BSE
- Today’s highest price of Gland Pharma Ltd is ₹1704.95.
- Today’s lowest price of Gland Pharma Ltd is ₹1670.
PE Ratio of Gland Pharma Ltd is 39.99
PE ratio = Gland Pharma Ltd Market price per share / Gland Pharma Ltd Earnings per share
Today’s traded volume of Gland Pharma Ltd(GLAND) is 1.17L.
Today’s market capitalisation of Gland Pharma Ltd(GLAND) is ₹27609.92Cr.
| Gland Pharma Ltd(GLAND | Price |
|---|---|
52 Week High | ₹2220.95 |
52 Week Low | ₹1585.7 |
Gland Pharma Ltd(GLAND) share price is ₹1679.2. It is down -24.39% from its 52 Week High price of ₹2220.95
Gland Pharma Ltd(GLAND) share price is ₹1679.2. It is up 5.90% from its 52 Week Low price of ₹1585.7
| Gland Pharma Ltd(GLAND | Returns |
|---|---|
1 Day Returns | 3.35% |
1 Month Returns | -4.8% |
3 Month Returns | 1.76% |
1 Year Returns | -13.9% |